Parkinson disease (PD) is a progressive neurodegenerative disease that affects peripheral
organs as well as the central nervous system and involves a fundamental role of …

The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Leucine-rich repeat kinase 2 (LRRK2) is one of the most promising targets for Parkinson's
disease. LRRK2-targeting strategies have primarily focused on type 1 kinase inhibitors …

Parkinson's disease (PD) is the most common movement disorder with motor and nonmotor
signs. The current therapeutic regimen for PD is mainly symptomatic as the etio …

Animal models of adult-onset neurodegenerative diseases have enhanced the
understanding of the molecular pathogenesis of Alzheimer's disease, Parkinson's disease …

The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance
pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a …

Parkinson's disease (PD) is a neurodegenerative disorder that affects about 1.5% of the
global population over 65 years of age. A hallmark feature of PD is the degeneration of the …

Parkinson disease (PD) is a complex neurodegenerative disorder with both motor and
nonmotor symptoms owing to a spreading process of neuronal loss in the brain. At present …

Antagonism of protein–protein interactions (PPIs) with small molecules is becoming more
feasible as a therapeutic approach. Successful PPI inhibitors tend to target proteins …

Neurons are critically dependent on mitochondrial integrity based on specific morphological,
biochemical, and physiological features. They are characterized by high rates of metabolic …